{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:52:38Z","timestamp":1761238358286,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40262-016-0504-2","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T01:52:37Z","timestamp":1483926757000},"page":"1173-1183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-1526","authenticated-orcid":false,"given":"Phyllis","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Eley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayo","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Garimella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malaz","family":"AbuTarif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"issue":"5","key":"504_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.coviro.2013.06.014","volume":"3","author":"M Gao","year":"2013","unstructured":"Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013;3(5):514\u201320.","journal-title":"Curr Opin Virol."},{"key":"504_CR2","unstructured":"United States Food and Drug Administration. FDA approves new treatment for chronic hepatitis C genotype 3 infections. 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm455888.htm. Accessed 12 May 2016."},{"issue":"1","key":"504_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77\u201387.","journal-title":"Hepatology"},{"key":"504_CR4","doi-asserted-by":"crossref","unstructured":"Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60(1):98\u2013105.","DOI":"10.1002\/hep.27095"},{"key":"504_CR5","unstructured":"World Health Organization. WHO model list of essential medicines. 19th list. Apr 2015; amended Aug 2015. http:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/EML_2015_FINAL_amended_AUG2015.pdf?ua=1. Accessed 1 May 2016."},{"key":"504_CR6","unstructured":"Bifano M, Sevinsky H, Stonier M, Jiang H, Bertz RJ. Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4 [abstract no. O_15]. In: 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy: Cambridge (MA); 26\u201327 June 2013."},{"issue":"6","key":"504_CR7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/hep.24609","volume":"54","author":"RE Nettles","year":"2011","unstructured":"Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011;54(6):1956\u201365.","journal-title":"Hepatology"},{"key":"504_CR8","first-page":"S32","volume":"41","author":"N Thanneer","year":"2014","unstructured":"Thanneer N, Roy A, Sukumar P, Bandaru J, Carleen E. Best practices for preparation of pharmacometric analysis data sets. J Pharmacokinet Pharmacodyn. 2014;41:S32.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"504_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J."},{"key":"504_CR10","first-page":"S41","volume":"41","author":"P Chan","year":"2014","unstructured":"Chan P, Zhu L, Eley T, Bifano M, Hughes E, Bertz R, et al. Exposure-safety analysis for asunaprevir and daclatasvir in DUAL combination in subjects with hepatitis C virus infection. J Pharmacokinet Pharmacodyn. 2014;41:S41. [Abstracts for conference poster presentations]","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"504_CR11","first-page":"S38","volume":"41","author":"L Zhu","year":"2014","unstructured":"Zhu L, Chan P, Eley T, Bifano M, Osawa M, Ueno T, et al. Exposure-efficacy analysis for daclatasvir and asunaprevir in DUAL combination in subjects with genotype 1b hepatitis C virus infection. J Pharmacokinet Pharmacodyn. 2014;41:S38. [Abstracts for conference poster presentations]","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"504_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3851\/IMP2941","volume":"20","author":"T Garimella","year":"2015","unstructured":"Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;20(5):535\u201343.","journal-title":"Antivir Ther."},{"issue":"9","key":"504_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00535-005-1636-6","volume":"40","author":"Y Kawamura","year":"2005","unstructured":"Kawamura Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol. 2005;40(9):901\u20136.","journal-title":"J Gastroenterol"},{"issue":"S1","key":"504_CR14","first-page":"1004A","volume":"54","author":"M Bifano","year":"2011","unstructured":"Bifano M, Sevinsky H, Persson A, Chung E, Wind-Rotolo M, Hwang C, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects. Hepatology. 2011;54(S1):1004A.","journal-title":"Hepatology"},{"issue":"9","key":"504_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40261-014-0219-9","volume":"34","author":"T Eley","year":"2014","unstructured":"Eley T, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, et al. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clin Drug Investig. 2014;34(9):661\u201371.","journal-title":"Clin Drug Investig"},{"key":"504_CR16","unstructured":"Eley T, You X, Huang S-P, Symonds W, Li W, Sherman D, et al. Evaluation of drug interaction potential between daclatasvir and sofosbuvir [abstract no. O_14]. In: 8th International workshop on clinical pharmacology of hepatitis therapy: Cambridge (MA); 26\u201327 June 2013."},{"issue":"5","key":"504_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40261-015-0279-5","volume":"35","author":"M Bifano","year":"2015","unstructured":"Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015;35(5):281\u20139.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"504_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3851\/IMP2718","volume":"19","author":"M Bifano","year":"2014","unstructured":"Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, et al. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther. 2014;19(5):511\u20139.","journal-title":"Antivir Ther."},{"issue":"9","key":"504_CR19","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1128\/AAC.00478-15","volume":"59","author":"T Garimella","year":"2015","unstructured":"Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, et al. Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother. 2015;59(9):5503\u201310.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-016-0504-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:24:09Z","timestamp":1659101049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-016-0504-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0504-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2017,1,9]]},"assertion":[{"value":"9 January 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The studies described in this report were funded by Bristol-Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P. Chan, L. Zhu, R. Bertz, T. Garimella, and M. AbuTarif are all employees of Bristol-Myers Squibb. M. Bifano, T. Eley, and E. Hughes are former employees of Bristol-Myers Squibb and were employed by Bristol-Myers Squibb when the studies and analyses were conducted. M. Osawa and T. Ueno are employees of Bristol-Myers Squibb K.K. Hanbin Li of Quantitative Solutions was funded by Bristol-Myers Squib to carry out the modeling analyses reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved by the institutional review board\/independent ethics committee at each site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all study participants and\/or their legally authorized representative.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}